logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
03/06/2026
Insiders revealed that the space exploration technology company has set its initial public offering target price at $135 per share.
Latest
2 m ago
Shipping index Euroline futures continuous main contract fell 4% during the day, now at 3631.00 points.
5 m ago
Not afraid of falling yields, US bond shorts bet on strong non-farm payrolls to solidify rate hike expectations.
7 m ago
Maigemeet and others founded Zhiyuan Technology Company, which includes AI and robotics businesses.
8 m ago
The 2026 China International Mining Conference will feature a "major marketplace" for mining rights transactions.
8 m ago
Lezutica monoclonal antibody, a dual-target drug targeting IL-17A/F by Lijiu Pharmaceuticals, has been accepted for market application for the treatment of ankylosing spondylitis.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.